Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diperoxochloric acid (DPOCL) is a first-in-class small molecule New Chemical Entity (NCE) developed by Centaur Pharmaceuticals in collaboration with CytoTools AG for the treatment of diabetic foot ulcers. Formulated as a topical solution and marketed under the brand name WOXheal, it possesses a dual mechanism of action: it exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria and stimulates fibroblast growth to promote wound healing and closure. DPOCL received regulatory approval from the CDSCO in India in 2019 after successful Phase II and Phase III clinical trials, which demonstrated a 76% complete wound closure rate compared to 57.5% in the control group. It was launched in India in 2020 as a first-in-world treatment for this indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diperoxochloric acid.